A worker repackages vaccines in a factory owned by Indonesia’s pharmaceutical firm Bio Farma in Bandung, West Java. ANTARA FOTO/Raisan Al Farisi/wsj/18.

Indonesia is set to become the hub for Chinese vaccines in Southeast Asia. How does the country benefit?

If Indonesia can maximise its role as the hub for the production and distribution of Chinese COVID-19 vaccines for Southeast Asia region, the country may gain profits.
Researchers develop COVID-19 vaccines in Bio Farma, Indonesia’s pharmaceutical holding company Bio Farma in Bandung, West Java. ANTARA FOTO/Dhemas Reviyanto/foc

Delaying a COVID‑19 vaccination program may cost Indonesia US$44 billion

Delaying a widespread vaccination program would cause not only higher causalities but also long term economic loss for Indonesia.

Contact Anda for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision